Measurement of human cytochrome P450 enzyme induction based on mesalazine and mosapride citrate treatments using a luminescent assay

Biomolecules and Therapeutics

Volumn 23, Issue 5, 2015, Pages 486-492

  Kim, Young Hoon ^a   Bae, Young Ji ^a   Kim, Hyung Soo ^a   Cha, Hey Jin ^a   Yun, Jae Suk ^a   Shin, Ji Soon ^a   Seong, Won Keun ^a   Lee, Yong Moon ^b   Han, Kyoung Moon ^a,b  

^a Ministry of Food and Drug Safety   (South Korea)

^b Chungbuk National University   (South Korea)

Author keywords

CYP; Human hepatocytes; Luminescent assay; Mesalazine; Mosapride citrate

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; MESALAZINE; MESSENGER RNA; MOSAPRIDE;

ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; CYP3A4 GENE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INDUCTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIVER CELL; LUMINESCENT ASSAY; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84940373215     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2015.041     Document Type: Article

References (13)

1. Auld, D. S., Veith, H. and Cali, J. J. (2013) Bioluminescent assays for cytochrome CYP enzymes. Methods Mol. Biol. 987, 1-9.
2. Bosetti, A., Sobol, M., Ma, D., Good T., Liu, D. and Cali, J. J. (2005) Bioluminescent cytochrome CYP assays. Pharmacologyonline 3, 9-18.
3. Cali, J. J., Ma, D., Sobol, M., Simpson, D. J., Frackman, S., Good, T. D., Daily, W. J. and Liu, D. (2006) Luminogenic cytochrome CYP assays. Expert Opin. Drug Metab. Toxicol. 2, 629-645.
4. Cali, J. J., Niles, A., Valley, M. P., O'Brien, M. A., Riss, T. L. and Shultz, J. (2008) Bioluminescent assays for ADMET. Expert Opin. Drug Metab. Toxicol. 4, 103-120.
5. Garcia, M. C., Ma, D., Dicioccio, A. T. and Cali, J. (2008) The use of a high-throughput luminescent method to assess CYP3A enzyme induction in cultured rat hepatocytes. In Vitro Cell. Dev. Biol. Anim. 44, 129-134.
6. Kim, S. H., Park, Y. S., Kim, J. M., Park, H. J., Lee, M. H., Park, H. K., Kim, Y. J., Cho, S. H., Shaw, L. M. and Kang, J. S. (2012) Pharmacokinetic and bioavailability studies of 5 mg mosapride tablets in healthy Korean volunteers. Int. J. Clin. Pharmacol. Ther. 50, 524-531.
7. Mann, H. J. (2006) Drug-associated disease: cytochrome CYP interactions. Crit. Care Clin. 22, 329-345
8. Ofotokun, I. (2005) Sex differences in the pharmacologic effects of antiretroviral drugs: potential roles of drug transporters and phase 1 and 2 metabolizing enzymes. Top. HIV Med. 13, 79-83.
9. Ogu, C. C. and Maxa, J. L. (2000) Drug interactions due to cytochrome CYP. Proc. (Bayl. Univ. Med. Cent.) 13, 421-423.
10. Parkinson, A., Mudra, D. R., Johnson, C., Dwyer, A. and Carroll, K. M. (2004). The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome CYP enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol. Appl. Pharmacol. 199, 193-209.
11. Wiersma, H., Escher, J. C., Dilger, K., Trenk, D., Benninga, M. A., van Boxtel, C. J. and Taminiau, J. (2004) Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease. Inflamm. Bowel Dis. 10, 626-631.
12. Wrighton, S. A. and Stevens, J. C. (1992) The human hepatic cytochromes CYP involved in drug metabolism. Crit. Rev. Toxicol. 22, 1-21.
13. Zanger, U. M. and Schwab, M. (2013) Cytochrome CYP enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103-141.